CD19 and lymphoma: Knowing the essential role of CD19 in the survival and CXCL12-induced migration of both BCWM.1 and DHL6 lymphoma cells, we tested whether treatment with anti-CD19 monoclonal antibodies (mAbs) had any effect on these cells.